103 related articles for article (PubMed ID: 19762526)
1. In situ evidence of KRAS amplification and association with increased p21 levels in non-small cell lung carcinoma.
Wagner PL; Perner S; Rickman DS; LaFargue CJ; Kitabayashi N; Johnstone SF; Weir BA; Meyerson M; Altorki NK; Rubin MA
Am J Clin Pathol; 2009 Oct; 132(4):500-5. PubMed ID: 19762526
[TBL] [Abstract][Full Text] [Related]
2. Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma.
Wagner PL; Stiedl AC; Wilbertz T; Petersen K; Scheble V; Menon R; Reischl M; Mikut R; Rubin MA; Fend F; Moch H; Soltermann A; Weder W; Altorki NK; Perner S
Lung Cancer; 2011 Oct; 74(1):118-23. PubMed ID: 21477882
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Kras gene mutation and copy number gain in non-small cell lung cancer.
Sasaki H; Hikosaka Y; Kawano O; Moriyama S; Yano M; Fujii Y
J Thorac Oncol; 2011 Jan; 6(1):15-20. PubMed ID: 21150464
[TBL] [Abstract][Full Text] [Related]
4. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic activating mutations are associated with local copy gain.
Modrek B; Ge L; Pandita A; Lin E; Mohan S; Yue P; Guerrero S; Lin WM; Pham T; Modrusan Z; Seshagiri S; Stern HM; Waring P; Garraway LA; Chant J; Stokoe D; Cavet G
Mol Cancer Res; 2009 Aug; 7(8):1244-52. PubMed ID: 19671679
[TBL] [Abstract][Full Text] [Related]
6. KRAS mutations in non-small cell lung cancer.
Riely GJ; Marks J; Pao W
Proc Am Thorac Soc; 2009 Apr; 6(2):201-5. PubMed ID: 19349489
[TBL] [Abstract][Full Text] [Related]
7. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.
Beau-Faller M; Ruppert AM; Voegeli AC; Neuville A; Meyer N; Guerin E; Legrain M; Mennecier B; Wihlm JM; Massard G; Quoix E; Oudet P; Gaub MP
J Thorac Oncol; 2008 Apr; 3(4):331-9. PubMed ID: 18379349
[TBL] [Abstract][Full Text] [Related]
8. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
Onozato R; Kosaka T; Kuwano H; Sekido Y; Yatabe Y; Mitsudomi T
J Thorac Oncol; 2009 Jan; 4(1):5-11. PubMed ID: 19096300
[TBL] [Abstract][Full Text] [Related]
9. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.
Zhu CQ; da Cunha Santos G; Ding K; Sakurada A; Cutz JC; Liu N; Zhang T; Marrano P; Whitehead M; Squire JA; Kamel-Reid S; Seymour L; Shepherd FA; Tsao MS;
J Clin Oncol; 2008 Sep; 26(26):4268-75. PubMed ID: 18626007
[TBL] [Abstract][Full Text] [Related]
10. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Massarelli E; Varella-Garcia M; Tang X; Xavier AC; Ozburn NC; Liu DD; Bekele BN; Herbst RS; Wistuba II
Clin Cancer Res; 2007 May; 13(10):2890-6. PubMed ID: 17504988
[TBL] [Abstract][Full Text] [Related]
11. Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using LightCycler.
Sasaki H; Okuda K; Kawano O; Endo K; Yukiue H; Yokoyama T; Yano M; Fujii Y
Oncol Rep; 2007 Sep; 18(3):623-8. PubMed ID: 17671710
[TBL] [Abstract][Full Text] [Related]
12. Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis.
Fassina A; Gazziero A; Zardo D; Corradin M; Aldighieri E; Rossi GP
J Clin Pathol; 2009 Dec; 62(12):1096-102. PubMed ID: 19640859
[TBL] [Abstract][Full Text] [Related]
13. A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases.
Monaco SE; Nikiforova MN; Cieply K; Teot LA; Khalbuss WE; Dacic S
Hum Pathol; 2010 Jan; 41(1):94-102. PubMed ID: 19740513
[TBL] [Abstract][Full Text] [Related]
14. HER2 gene mutations in non-small cell lung carcinomas: concurrence with Her2 gene amplification and Her2 protein expression and phosphorylation.
Suzuki M; Shiraishi K; Yoshida A; Shimada Y; Suzuki K; Asamura H; Furuta K; Kohno T; Tsuta K
Lung Cancer; 2015 Jan; 87(1):14-22. PubMed ID: 25468202
[TBL] [Abstract][Full Text] [Related]
15. Whole genome gene copy number profiling of gastric cancer identifies PAK1 and KRAS gene amplification as therapy targets.
Qian Z; Zhu G; Tang L; Wang M; Zhang L; Fu J; Huang C; Fan S; Sun Y; Lv J; Dong H; Gao B; Su X; Yu D; Zang J; Zhang X; Ji J; Ji Q
Genes Chromosomes Cancer; 2014 Nov; 53(11):883-94. PubMed ID: 24935174
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
[TBL] [Abstract][Full Text] [Related]
17. EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy.
Italiano A; Cortot AB; Ilie M; Martel-Planche G; Fabas T; Pop D; Mouroux J; Hofman V; Hofman P; Pedeutour F
Int J Cancer; 2009 Nov; 125(10):2479-82. PubMed ID: 19681124
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.
Takahashi T; Sonobe M; Kobayashi M; Yoshizawa A; Menju T; Nakayama E; Mino N; Iwakiri S; Sato K; Miyahara R; Okubo K; Manabe T; Date H
Ann Surg Oncol; 2010 Mar; 17(3):889-97. PubMed ID: 20183914
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers.
Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Ishizuka T; Saito R; Nakajima T; Mori M
Int J Oncol; 2007 Jul; 31(1):169-73. PubMed ID: 17549418
[TBL] [Abstract][Full Text] [Related]
20. Enhancing detection of circulating tumor cells with activating KRAS oncogene in patients with colorectal cancer by weighted chemiluminescent membrane array method.
Yang MJ; Chiu HH; Wang HM; Yen LC; Tsao DA; Hsiao CP; Chen YF; Wang JY; Lin SR
Ann Surg Oncol; 2010 Feb; 17(2):624-33. PubMed ID: 19937133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
